Incretin Mimetics Market Size to Hit USD 37.71 Billion by 2033

Incretin Mimetics Market Size, Share, Growth, Segmental Analysis, By Drug Class (GLP-1 Receptor Agonists — Exenatide, Liraglutide, Semaglutide, Dulaglutide, Albiglutide, Lixisenatide; DPP-4 Inhibitors — Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Vildagliptin; GIP/GLP-1 Dual Agonists — Tirzepatide; Others), By Route of Administration (Subcutaneous Injectable, Oral), By Dosage Form (Pre-filled Pens, Vials, Tablets), By Therapeutic Application (Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Disease Risk Reduction, Others), By End User (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Apr, 2026
  • Report ID: 441
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Incretin Mimetics Market Size to Hit USD 37.71 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description and Scope

  • 1.2 Research Objectives

  • 1.3 Key Assumptions and Limitations

  • 1.4 Target Audience

2. Executive Summary

  • 2.1 Market Overview and Snapshot

  • 2.2 Key Market Findings and Highlights

  • 2.3 Market Size Estimation and Forecast Summary

  • 2.4 Key Trends at a Glance

  • 2.5 Recommendations for Market Participants

3. Research Methodology

  • 3.1 Research Design and Approach

  • 3.2 Primary Research (Endocrinologists, Diabetologists, Hospital Pharmacists, KOL Interactions, Pharma R&D Heads)

  • 3.3 Secondary Research (Annual Reports, FDA/EMA/CDSCO Drug Approval Databases, IDF Diabetes Atlas, WHO NCD Reports, ADA/EASD Guidelines, ClinicalTrials.gov)

  • 3.4 Top-Down and Bottom-Up Estimation Approach

  • 3.5 Data Triangulation and Validation

  • 3.6 Market Forecast Assumptions and Key Parameters

4. Market Overview

  • 4.1 Introduction to Incretin Mimetics and Their Role in Metabolic Disease Management

  • 4.2 Historical Market Background and Evolution (First-Generation GLP-1 Agonists → Long-Acting Once-Weekly → Oral Incretins → Dual/Triple Agonists)

  • 4.3 Market Scope and Definition

  • 4.4 Parent Market and Adjacent Market Analysis (Anti-Diabetic Drugs, Obesity Therapeutics, Cardiovascular Metabolic Medicines)

  • 4.5 Regulatory Overview (FDA NDA/BLA, EMA MAA, CDSCO Drug Approval, ICH M7/M9, GLP-1 Biosimilar Regulatory Frameworks, EU MDR for Drug-Device Combinations)

  • 4.6 Technology and Product Innovation Timeline (Byetta → Victoza → Ozempic/Rybelsus → Mounjaro → Tirzepatide → Next-Gen Triple Agonists)

  • 4.7 Injectable vs. Oral Incretin Mimetics: Clinical Efficacy, Patient Adherence, and Market Access Comparison

  • 4.8 Incretin Mimetics vs. SGLT-2 Inhibitors vs. DPP-4 Inhibitors: Comparative Mechanism, Outcomes, and Prescribing Trends

5. Market Dynamics

  • 5.1 Market Drivers

    • 5.1.1 Rising Global Prevalence of Type 2 Diabetes Mellitus — 537 Million Adults (IDF 2021) Rising to 643 Million by 2030

    • 5.1.2 Growing Global Epidemic of Obesity Expanding Therapeutic Addressable Market Beyond Diabetes (GLP-1 for Weight Management)

    • 5.1.3 Accelerating Clinical Evidence of Cardiovascular, Renal, and Hepatic Benefits Broadening Label Extensions for GLP-1 Agonists

    • 5.1.4 Rapid Adoption of Once-Weekly and Oral Formulations Improving Patient Adherence and Long-Term Therapy Compliance

    • 5.1.5 Strong FDA/EMA Regulatory Support — Fast-Track, Priority Review, and Expanded Indications (Semaglutide Wegovy, Ozempic CV, Tirzepatide SURMOUNT)

    • 5.1.6 Significant R&D Investment in Next-Generation Dual/Triple GLP-1/GIP/Glucagon Receptor Co-Agonists

    • 5.1.7 Expansion of Biosimilar Incretin Mimetics Improving Affordability and Access in Emerging Markets

  • 5.2 Market Restraints

    • 5.2.1 High Drug Acquisition and Out-of-Pocket Costs Limiting Patient Access, Particularly in LMICs and Uninsured U.S. Patients

    • 5.2.2 Manufacturing Supply Shortages of Peptide Intermediates Creating Drug Supply Constraints (Ozempic Shortage 2022–2024)

    • 5.2.3 Gastrointestinal Adverse Events (Nausea, Vomiting, Diarrhea) Causing Treatment Discontinuation in a Subset of Patients

    • 5.2.4 Growing Competition from SGLT-2 Inhibitors, DPP-4 Inhibitors, and Combination Drug Classes Limiting Market Share Growth

    • 5.2.5 Patent Expiry of Key Branded GLP-1 Products Opening Market to Generic and Biosimilar Entrants

  • 5.3 Market Opportunities

    • 5.3.1 Oral GLP-1 Formulation Innovation (Rybelsus, Next-Gen Oral Semaglutide, Orforglipron) — Addressing Needle Aversion and Compliance Gap

    • 5.3.2 Expansion of Triple Agonist Programs (GLP-1/GIP/Glucagon) for Greater Cardiometabolic Benefit (LY3437943, Retatrutide)

    • 5.3.3 Biosimilar GLP-1 Launches in India, China, and Latin America Enabling Mass-Market Diabetes Management

    • 5.3.4 Label Extension into NAFLD/NASH, Polycystic Ovary Syndrome (PCOS), Heart Failure, and CKD Management

    • 5.3.5 AI and Computational Biology-Driven Peptide Engineering for Next-Generation Incretin Analog Discovery (SmithKline AI-Peptide, Novo Nordisk AI Platform)

    • 5.3.6 Combination Therapies — Incretin Mimetics with Basal Insulin, SGLT-2, and Long-Acting Amylin Analogs

    • 5.3.7 Sustainable and Patient-Friendly Delivery Systems — Recyclable Autoinjectors, Smart Pen Devices with Dose Tracking

  • 5.4 Market Challenges

    • 5.4.1 Cold-Chain Logistics and Peptide Stability Requirements Driving Complex and Costly Distribution Infrastructure

    • 5.4.2 Prescriber Education Gaps on Appropriate Patient Selection, Titration Protocols, and Combination Use Optimization

    • 5.4.3 Managing Rapid Market Share Loss Post-Patent Expiry in the Face of Aggressive Biosimilar Pricing Strategies

    • 5.4.4 Balancing Fast-Cycle AI-Driven Drug Innovation with Rigorous GCP/GMP and Post-Marketing Pharmacovigilance Requirements

6. Market Trends and Key Insights

  • 6.1 Dominant Surge of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonists (Tirzepatide) as Standard of Care in T2DM and Obesity

  • 6.2 Accelerating Adoption of Once-Weekly Subcutaneous Formulations and Transition to Oral Incretin Mimetics (Rybelsus, Orforglipron)

  • 6.3 Label Expansions Beyond Diabetes — Obesity (Wegovy), Cardiovascular (Ozempic CV), and Emerging NASH/CKD Indications

  • 6.4 AI-Driven Peptide Engineering Accelerating Next-Generation Multi-Agonist Development — Triple Receptor Co-Agonists in Clinical Trials

  • 6.5 Growing Biosimilar Pipeline — Lupin Liraglutide, Glenmark Lirafit, Biocon-Zentiva Liraglutide Creating Competitive Market Dynamics

  • 6.6 Smart Injector Platforms with Dose-Tracking, Bluetooth Connectivity, and App Integration (NovoPen 6 Echo Plus, Lilly Connected Pen)

  • 6.7 Strong Investor Confidence — Novo Nordisk and Eli Lilly Market Cap Surging, Reflecting Widening Cardiometabolic TAM

  • 6.8 Integration of Precision Medicine and Pharmacogenomics for Optimal Incretin Drug Selection and Dosing Personalization

7. Impact Assessment

  • 7.1 Impact of COVID-19 on the Incretin Mimetics Market

    • 7.1.1 Pre-COVID Market Scenario

    • 7.1.2 Pandemic Impact: Supply Chain Disruptions, Delayed Clinical Trials, Reduced Elective Diabetes Consultations

    • 7.1.3 Post-COVID Rebound: Telemedicine-Enabled Prescribing, Accelerated Obesity Drug Demand, and Manufacturing Scale-Up

  • 7.2 Macroeconomic Indicators and Their Influence on Market Growth

  • 7.3 Impact of U.S. IRA Drug Pricing Negotiation (Ozempic/Mounjaro Pricing Pressure), EU HTA Regulation, and Insurance Coverage Mandates

  • 7.4 Geopolitical Factors — China API Supply Constraints, U.S.-China Pharma Trade Policies, and India CDSCO Biosimilar Regulatory Landscape

8. Strategic Framework Analysis

  • 8.1 Value Chain Analysis

    • 8.1.1 Amino Acid and Peptide Precursor Raw Material Suppliers

    • 8.1.2 Active Pharmaceutical Ingredient (API) and Peptide Synthesis Manufacturers

    • 8.1.3 Drug Formulation and Fill-Finish Manufacturers (Cartridges, Pre-Filled Pens, Vials, Oral Tablets)

    • 8.1.4 Drug-Device Combination System Developers (Autoinjectors, Smart Pens, Oral Delivery Systems)

    • 8.1.5 Regulatory and Pharmacovigilance Partners

    • 8.1.6 Distribution and Cold-Chain Logistics Providers

    • 8.1.7 End Users — Hospitals, Retail and Online Pharmacies, Clinics, Homecare Settings

  • 8.2 Supply Chain Analysis and Risk Assessment (Peptide Intermediate Supply Constraints, Cold-Chain Vulnerability)

  • 8.3 Porter's Five Forces Analysis

    • 8.3.1 Threat of New Entrants (Biosimilar Manufacturers, AI-Native Peptide Biotechs)

    • 8.3.2 Bargaining Power of Buyers (Hospital Formulary Committees, National Health Systems, PBMs)

    • 8.3.3 Bargaining Power of Suppliers (Peptide API Manufacturers, Autoinjector Device OEMs)

    • 8.3.4 Threat of Substitute Therapies (SGLT-2 Inhibitors, DPP-4 Inhibitors, Bariatric Surgery, Amylin Analogs)

    • 8.3.5 Competitive Rivalry Among Existing Players

  • 8.4 SWOT Analysis of the Overall Market

  • 8.5 Pricing Analysis and Trends by Product Type, Formulation, and Region

  • 8.6 Technology Landscape and Innovation Matrix

    • 8.6.1 Oral GLP-1 Delivery Innovation — Enteric Coating, Nanoparticle Encapsulation, Absorption Enhancers

    • 8.6.2 Once-Weekly Injectable Platforms — Long-Acting Peptide Formulation Engineering

    • 8.6.3 Dual/Triple Receptor Co-Agonist Drug Design (GLP-1/GIP/Glucagon Multi-Target Approach)

    • 8.6.4 Smart Autoinjector and Connected Pen Device Platforms (Dose Tracking, App Integration, Bluetooth)

    • 8.6.5 AI and Computational Biology for Peptide Analog Discovery and Optimization

    • 8.6.6 Biosimilar Peptide Synthesis Technology — Recombinant DNA, SPPS, and Bioequivalence Validation

  • 8.7 IP and Patent Landscape (Key GLP-1 Patent Expiries, Biosimilar Exclusivity Cliffs, Novo Nordisk/Eli Lilly Portfolio)

  • 8.8 Clinical Pipeline Analysis — Phase I/II/III Trials for Next-Generation Incretin Compounds (Orforglipron, Retatrutide, Mazdutide, LY3437943)

  • 8.9 Regulatory and Standards Landscape by Region (FDA NDA/BLA, EMA MAA, CDSCO, NMPA, PMDA, ICH M7/M9, GMP Frameworks)

  • 8.10 Drivers Impact Analysis on CAGR

9. Global Incretin Mimetics Market — By Product Type / Drug Type

  • 9.1 Overview and Market Size, 2026–2033

  • 9.2 GLP-1 Receptor Agonists

    • 9.2.1 Semaglutide (Ozempic / Wegovy / Rybelsus — Novo Nordisk)

    • 9.2.2 Liraglutide (Victoza / Saxenda — Novo Nordisk; Biosimilars: Glenmark Lirafit, Biocon-Zentiva)

    • 9.2.3 Exenatide (Byetta / Bydureon BCise — AstraZeneca; Biosimilars: Generic Exenatide Extended-Release)

    • 9.2.4 Dulaglutide (Trulicity — Eli Lilly)

    • 9.2.5 Albiglutide (Tanzeum — GSK)

    • 9.2.6 Market Size, Share, and Forecast (56.4% Dominant Share; Proven CVD Outcomes, Once-Weekly Convenience)

  • 9.3 Dual / Triple Agonists (GLP-1/GIP and GLP-1/GIP/Glucagon Co-Agonists)

    • 9.3.1 Tirzepatide (Mounjaro / Zepbound — Eli Lilly)

    • 9.3.2 Next-Generation Triple Agonists in Development (Retatrutide, LY3437943)

    • 9.3.3 Market Size, Share, and Forecast (Fastest Growing — 6.5% CAGR: Superior Glycemic and Weight Loss Outcomes)

  • 9.4 Combination Therapies

    • 9.4.1 GLP-1 Agonist + Basal Insulin Fixed-Ratio Combinations (Xultophy — Novo Nordisk; Soliqua — Sanofi)

    • 9.4.2 GLP-1 + SGLT-2 Inhibitor Combination Regimens

    • 9.4.3 GLP-1 + Long-Acting Amylin Analog Combinations (CagriSema — Novo Nordisk Pipeline)

    • 9.4.4 Market Size, Share, and Forecast

  • 9.5 DPP-4 Inhibitors (as Adjacent Drug Type within Incretin Class)

    • 9.5.1 Sitagliptin (Januvia — Merck & Co.)

    • 9.5.2 Saxagliptin (Onglyza — AstraZeneca)

    • 9.5.3 Alogliptin (Nesina — Takeda Pharmaceutical)

    • 9.5.4 Linagliptin (Tradjenta — Boehringer Ingelheim / Eli Lilly)

    • 9.5.5 Market Size, Share, and Forecast (34.4% Share in 2025 per Coherent Market Insights: Established Oral Use)

10. Global Incretin Mimetics Market — By Route of Administration

  • 10.1 Overview and Market Size, 2026–2033

  • 10.2 Subcutaneous Injection

    • 10.2.1 Market Size, Share, and Forecast (70.4% Dominant Share: Predictable Pharmacokinetics, Proven Once-Weekly Platforms)

    • 10.2.2 Key Drivers: Long-Acting Injectables, Auto-Injector Adoption, Pre-Filled Pen Ecosystem

  • 10.3 Oral Administration

    • 10.3.1 Market Size, Share, and Forecast (7.0% CAGR — Fastest Growing: Rybelsus, Next-Gen Oral GLP-1 Analogs)

    • 10.3.2 Key Drivers: Needle Aversion, Improved Bioavailability via Enteric Coatings and Nanocarrier Delivery

  • 10.4 Intravenous

    • 10.4.1 Market Size, Share, and Forecast

    • 10.4.2 Key Applications: Clinical Trial Settings, Acute Hospital-Based Metabolic Management

11. Global Incretin Mimetics Market — By Dosage Form

  • 11.1 Overview and Market Size, 2026–2033

  • 11.2 Pre-Filled Pens

    • 11.2.1 Standard Pre-Filled Injection Pens

    • 11.2.2 Smart Connected Pens (Bluetooth Dose Tracking — NovoPen 6, Lilly Connected Pen)

    • 11.2.3 Market Size, Share, and Forecast (58.4% Dominant Share: Ease-of-Use, Dose Accuracy, Patient Autonomy)

  • 11.3 Oral Tablets

    • 11.3.1 Standard Oral Tablets (Rybelsus — Oral Semaglutide)

    • 11.3.2 Extended-Release Oral Tablets and Next-Generation Oral GLP-1 Candidates

    • 11.3.3 Market Size, Share, and Forecast

  • 11.4 Vials

    • 11.4.1 Market Size, Share, and Forecast (6.6% CAGR — Fastest Growing: Clinical/Institutional Bulk Dispensing Applications)

    • 11.4.2 Key Applications: Hospital-Based Administration, Research, Compounding Pharmacies, Cost-Sensitive Markets

  • 11.5 Others (Autoinjector Kits, Implantable Devices — ITCA 650 Exenatide Mini-Pump)

    • 11.5.1 Market Size, Share, and Forecast

12. Global Incretin Mimetics Market — By Therapeutic Application

  • 12.1 Overview and Market Size, 2026–2033

  • 12.2 Type 2 Diabetes Mellitus (T2DM)

    • 12.2.1 First-Line Monotherapy Applications

    • 12.2.2 Combination Therapy in Insulin-Naïve Patients

    • 12.2.3 Add-On Therapy in Inadequately Controlled Patients

    • 12.2.4 Market Size, Share, and Forecast (54.4% Dominant Share: Primary Indication, Wide Clinical Guideline Integration)

  • 12.3 Obesity and Weight Management

    • 12.3.1 Non-Diabetic Obesity (BMI ≥30 or ≥27 with Comorbidities)

    • 12.3.2 Obesity-Related Co-Morbidities (Metabolic Syndrome, PCOS, OSA)

    • 12.3.3 Market Size, Share, and Forecast (Fastest Growing — 6.8% CAGR: Wegovy/Zepbound, SURMOUNT-1 Outcomes, Policy Shifts)

  • 12.4 Cardiovascular Risk Management

    • 12.4.1 High-Risk T2D Patients with Established Atherosclerotic CVD

    • 12.4.2 Heart Failure with Preserved Ejection Fraction (HFpEF)

    • 12.4.3 Market Size, Share, and Forecast (Ozempic CV Approval, LEADER and SUSTAIN-6 Trial Evidence)

  • 12.5 Others (NAFLD/NASH, Chronic Kidney Disease, PCOS, Alzheimer's Disease Prevention Research)

    • 12.5.1 Market Size, Share, and Forecast

13. Global Incretin Mimetics Market — By End User

  • 13.1 Overview and Market Size, 2026–2033

  • 13.2 Hospitals

    • 13.2.1 Market Size, Share, and Forecast (48.5% Dominant Share: Specialist Management, Inpatient Initiation, Real-World Surveillance)

    • 13.2.2 Key Role: CSSD Formulary Management, Endocrinology Rounds, Pharmacist-Led Diabetes Counseling

  • 13.3 Clinics

    • 13.3.1 Diabetes and Endocrinology Specialty Clinics

    • 13.3.2 Metabolic Wellness and Obesity Management Clinics

    • 13.3.3 Market Size, Share, and Forecast (Fastest Growing — 6.9% CAGR: Decentralized, Patient-Centric Metabolic Care)

  • 13.4 Homecare Settings

    • 13.4.1 Market Size, Share, and Forecast

    • 13.4.2 Self-Administration via Pre-Filled Pens and Connected Devices — Growing Tele-Diabetes Model

  • 13.5 Research Institutes

    • 13.5.1 Market Size, Share, and Forecast

    • 13.5.2 Academic Clinical Trials, Pharmacokinetics Studies, Biosimilar Development Research

14. Global Incretin Mimetics Market — By Distribution Channel

  • 14.1 Overview and Market Size, 2026–2033

  • 14.2 Hospital Pharmacies

    • 14.2.1 Market Size, Share, and Forecast (40.2% Dominant Share: Inpatient, Specialist-Initiated, Formulary-Managed)

  • 14.3 Retail Pharmacies

    • 14.3.1 Market Size, Share, and Forecast

    • 14.3.2 Community Access, Patient Adherence Counseling, and Over-the-Counter Adjacent Diabetes Products

  • 14.4 Online Pharmacies

    • 14.4.1 Market Size, Share, and Forecast (Fastest Growing Channel: Telehealth-Linked e-Prescribing, Home Delivery)

    • 14.4.2 Key Platforms: Amazon Pharmacy, NovoCare, Lilly Cares, and Telehealth Pharmacy Tie-Ups

15. Global Incretin Mimetics Market — By Region

  • 15.1 Market Overview by Geography

  • 15.2 North America

    • 15.2.1 Market Size and Forecast (41.4% Dominant Share)

    • 15.2.2 United States (~USD 7.66 Billion in 2025 — Novo Nordisk, Eli Lilly Innovation Hub, FDA Fast-Track Leadership)

    • 15.2.3 Canada

    • 15.2.4 Mexico

    • 15.2.5 Key Drivers, Trends, and Market Dynamics

  • 15.3 Europe

    • 15.3.1 Market Size and Forecast (Steady Growth — EMA Approvals, EASD Guideline Integration)

    • 15.3.2 Germany (Largest European Market — Precision Peptide Manufacturing, Biopharma Ecosystem)

    • 15.3.3 United Kingdom

    • 15.3.4 France

    • 15.3.5 Italy

    • 15.3.6 Spain

    • 15.3.7 Russia

    • 15.3.8 Rest of Europe

    • 15.3.9 Key Drivers, Trends, and Market Dynamics

  • 15.4 Asia Pacific

    • 15.4.1 Market Size and Forecast (Fastest Growing Region — 7.2% CAGR)

    • 15.4.2 China (Domestic GLP-1 Development — Hengrui, CNNC, Pegylated GLP-1 Advances)

    • 15.4.3 India (Biosimilar Incretin Leadership — Glenmark Lirafit, Biocon, Dr. Reddy's Saxagliptin)

    • 15.4.4 Japan (PMDA Approved Semaglutide, Dulaglutide — Aging Diabetic Population)

    • 15.4.5 South Korea

    • 15.4.6 Australia

    • 15.4.7 ASEAN (Thailand, Vietnam, Indonesia, Philippines)

    • 15.4.8 Rest of Asia Pacific

    • 15.4.9 Key Drivers, Trends, and Market Dynamics

  • 15.5 Latin America

    • 15.5.1 Market Size and Forecast

    • 15.5.2 Brazil

    • 15.5.3 Mexico

    • 15.5.4 Argentina

    • 15.5.5 Rest of Latin America

    • 15.5.6 Key Drivers, Trends, and Market Dynamics

  • 15.6 Middle East & Africa

    • 15.6.1 Market Size and Forecast

    • 15.6.2 GCC Countries (Saudi Arabia, UAE, Kuwait, Others)

    • 15.6.3 Israel

    • 15.6.4 South Africa

    • 15.6.5 North Africa and Central Africa

    • 15.6.6 Rest of Middle East & Africa

    • 15.6.7 Key Drivers, Trends, and Market Dynamics

16. Competitive Landscape

  • 16.1 Market Structure and Competitiveness Overview (Highly Concentrated — Novo Nordisk 18%+ Share, Top 5 Players Hold 35%)

  • 16.2 Market Share Analysis of Key Players

  • 16.3 Competitive Positioning Matrix

  • 16.4 Key Strategies Adopted by Market Leaders

    • 16.4.1 Portfolio Expansion — Semaglutide Multi-Indication Strategy (T2DM, Obesity, CVD, CKD, NASH)

    • 16.4.2 Manufacturing Scale-Up — Novo Nordisk and Eli Lilly Investing Billions in Peptide Synthesis and Fill-Finish Capacity

    • 16.4.3 Smart Delivery Device Innovation — Connected Pen Platforms and AI-Assisted Dosing Adherence Systems

    • 16.4.4 Biosimilar Entry Strategies — Glenmark, Biocon, Lupin, Dr. Reddy's Positioning in Emerging Markets

    • 16.4.5 Partnership-Led Pipeline Development — Zealand Pharma, Hanmi, Structure Therapeutics Collaborating with Major Pharma

  • 16.5 Recent Developments and Industry News (2024–2026)

  • 16.6 Clinical Pipeline and Next-Generation Product Analysis

17. Company Profiles
(The final report includes a complete list of companies)

  • 17.1 Novo Nordisk A/S

    • 17.1.1 Company Overview

    • 17.1.2 Financial Performance

    • 17.1.3 Product Portfolio

    • 17.1.4 Strategic Initiatives

    • 17.1.5 SWOT Analysis

  • 17.2 Eli Lilly and Company

  • 17.3 AstraZeneca PLC

  • 17.4 Sanofi S.A.

  • 17.5 Merck & Co., Inc.

  • 17.6 Takeda Pharmaceutical Company Limited

  • 17.7 Boehringer Ingelheim GmbH

  • 17.8 Pfizer Inc.

  • 17.9 GlaxoSmithKline PLC (GSK)

  • 17.10 Biocon Limited

  • 17.11 Glenmark Pharmaceuticals Ltd.

  • 17.12 Zealand Pharma A/S

  • 17.13 Hanmi Pharmaceutical Co., Ltd.

  • 17.14 Intarcia Therapeutics, Inc.

  • 17.15 Dr. Reddy's Laboratories Ltd.

18. Appendix

  • 18.1 Abbreviations and Acronyms

  • 18.2 List of Tables

  • 18.3 List of Figures

  • 18.4 About the Publisher

  • 18.5 Research Process and Data Sources

19. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.